Hims & Hers Health, Inc. $HIMS Shares Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC grew its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 427.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,582 shares of the company’s stock after buying an additional 27,211 shares during the quarter. Hsbc Holdings PLC’s holdings in Hims & Hers Health were worth $1,090,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Binnacle Investments Inc acquired a new stake in Hims & Hers Health in the third quarter worth approximately $28,000. Bogart Wealth LLC lifted its position in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the period. Geneos Wealth Management Inc. bought a new position in Hims & Hers Health during the 1st quarter valued at $30,000. Finally, Greenline Wealth Management LLC bought a new position in Hims & Hers Health during the 4th quarter valued at $36,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Patrick Harrison Carroll sold 23,726 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the sale, the insider owned 181,861 shares in the company, valued at $6,365,135. The trade was a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the sale, the chief operating officer owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. This trade represents a 3.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 167,161 shares of company stock valued at $5,041,152 over the last 90 days. 11.76% of the stock is owned by corporate insiders.

Hims & Hers Health Stock Up 0.0%

Shares of Hims & Hers Health stock opened at $34.40 on Tuesday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The firm has a market capitalization of $7.96 billion, a PE ratio of -382.19, a price-to-earnings-growth ratio of 96.75 and a beta of 2.35. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The stock’s fifty day moving average is $29.51 and its 200-day moving average is $26.33.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.20 EPS. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on HIMS shares. Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Bank of America raised their target price on Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a research note on Thursday, July 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $25.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 5th. Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Citigroup raised their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $30.70.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.